In analytical peptide synthesis, CJC-1295 No DAC purity defines the chemical integrity, sequence fidelity, and baseline reliability of the compound in preclinical models. This technical guide outlines the analytical protocols—including RP-HPLC, ESI-MS, and endotoxin screening—required to verify lot-to-lot consistency for laboratory research.
In analytical peptide synthesis, CJC-1295 No DAC purity defines the chemical integrity, sequence fidelity, and baseline reliability of the compound in preclinical models. This technical guide outlines the analytical protocols—including RP-HPLC, ESI-MS, and endotoxin screening—required to verify lot-to-lot consistency for laboratory research.
CJC-1295 No DAC purity refers to the percentage of intact, correctly sequenced 29-amino-acid peptide (Modified GRF 1-29) relative to synthesis truncations, deletion sequences, and chemical counter-ions. High-purity CJC-1295 No DAC is verified at ≥98% purity via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and accurate molecular mass identity confirmed through Electrospray Ionization Mass Spectrometry (ESI-MS).
Achieving this degree of chemical purity is essential for in vitro receptor binding assays and in vivo rodent models, where residual synthesis contaminants or unremoved TFA (trifluoroacetic acid) salts can introduce unwanted baseline toxicity or confound physiological data.
CJC-1295 No DAC, structurally identified as Modified GRF 1-29 (tetrasubstituted growth hormone-releasing hormone fragment), is a synthetic analog of endogenous GHRH. Its sequence incorporates specific amino acid substitutions at positions 2, 8, 15, and 27 (D-Ala2, Gln8, Ala15, and Leu27) designed to resist rapid enzymatic cleavage by dipeptidyl peptidase-IV (DPP-IV). Unlike native native peptides, these modifications preserve the active N-terminal domain required for receptor activation while extending its biological half-life in laboratory models.
It is vital for laboratory researchers to differentiate between CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 No DAC. The addition of the maleimido-propionic acid linker in the DAC variant allows covalent binding to circulating serum albumin, extending half-life significantly. Conversely, CJC-1295 No DAC lacks this conjugate, preserving short, physiological pulsatile activation of the growth hormone-releasing hormone receptor (GHRHR). Understanding these structural nuances is critical when selecting reagents for specific endocrine signaling trials. For expanded comparative metrics, view our research library hub covering GHRH sequence modifications.
Preclinical literature demonstrates that CJC-1295 No DAC acts as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR) located on pituitary somatotrophs. Upon receptor binding, the peptide stimulates the G alpha-s protein subunit, activating adenylate cyclase and elevating intracellular cyclic adenosine monophosphate (cAMP). This signaling cascade triggers protein kinase A (PKA) mobilization, leading to transcription and exocytosis of growth hormone (GH).
In rodent assays and cell-culture models, this selective stimulation induces a transient spike in circulating GH, which subsequently drives hepatic synthesis of insulin-like growth factor 1 (IGF-1). Because CJC-1295 No DAC does not permanently bind serum albumin, its clearance profile allows researchers to investigate physiological pulsatile GH release dynamics without causing receptor desensitization. Researchers evaluating downstream metabolic or tissue repair mechanisms frequently pair GHRH analogs with specific ghrelin mimetics to study synergistic signaling.
To establish absolute purity, raw peptide samples must undergo rigorous analytical verification using complementary chromatographic and mass-spectrometric techniques. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) separates the primary target peptide from synthesis impurities, such as D-amino acid racemization products, truncated sequences, or oxidation states. Chromatographic separation is achieved across a C18 stationary phase using a gradient of acetonitrile and water with 0.1% trifluoroacetic acid as an ion-pairing agent.
Analytical data is validated via UV detection at 214 nm and 280 nm. A compliant batch of CJC-1295 No DAC must display a sharp, symmetrical single peak representing no less than 98% total peak area integration. Concurrently, Electrospray Ionization Mass Spectrometry (ESI-MS) confirms the theoretical monoisotopic mass of 3367.9 Da. To review complete testing protocols, consult our detailed peptide purity HPLC analysis guide.
Bacterial endotoxins—specifically lipopolysaccharides (LPS) derived from Gram-negative outer cell membranes—represent a major source of experimental contamination. In vitro cellular cultures exposed to elevated endotoxin levels display unspecific cytokine release (e.g., TNF-alpha, IL-6), skewing transcriptomic and protein expression data. In live rodent models, high endotoxins induce systemic inflammatory responses that compromise experimental integrity.
Quantification of bacterial endotoxins is conducted using the Limulus Amebocyte Lysate (LAL) chromogenic assay. PX1 Research enforces strict threshold standards, ensuring that lot-specific endotoxin counts remain well below established preclinical limits (<0.1 EU/mg). This rigorous quality screening guarantees that cellular response patterns observed during assays are solely attributable to the bioactive compound rather than inflammatory impurities.
Lyophilized CJC-1295 No DAC is supplied as a sterile, vacuum-sealed cake or powder. For optimal stability, non-reconstituted vials should be stored in a controlled freezer environment at -20°C or -80°C, protected from light and moisture ingress. Under these conditions, the lyophilized peptide maintains chemical stability for up to 24 months.
When preparing solutions for laboratory evaluation, reconstitution should be performed using sterile Bacteriostatic Water (0.9% benzyl alcohol) or Sterile Water for Injection, depending on experimental design requirements. Solvent should be added down the inner glass wall of the vial to minimize shear force degradation, followed by gentle swirling without agitation. Reconstituted solutions must be stored at 2°C to 8°C and evaluated within short operational windows to avoid hydrolytic degradation or oxidation of sensitive residues.
When structuring comparative endocrine investigations, researchers often evaluate CJC-1295 No DAC alongside other GHRH analogs and growth hormone secretagogue receptor (GHSR) agonists. Understanding how these compounds differ in receptor selectivity, half-life, and physiological kinetics enables optimal experimental design.
For example, native Sermorelin represents the un-modified GHRH 1-29 sequence, featuring a rapid clearance profile due to DPP-IV enzymatic degradation. In contrast, CJC-1295 No DAC incorporates amino acid substitutions that resist enzymatic cleavage, extending its plasma half-life while retaining pulsatile release dynamics. When long-term, continuous elevation of GH is required, researchers often examine CJC-1295 DAC, which utilizes covalent albumin binding to sustain baseline levels for days. Additionally, combining GHRH analogs with selective GHSR agonists like Ipamorelin or GHRP-6 allows investigators to probe dual-pathway synergy for enhanced somatotroph secretagogue activity. To review receptor affinity data across classes, see our GHRH analogs mechanism overview.
Obtaining reproducible experimental outcomes requires research reagents produced under strict analytical oversight. Substandard, low-purity peptides often contain chemical artifacts, salt residues, and uncharacterized fragments that corrupt baseline laboratory measurements.
PX1 Research manufactures all research peptides within ISO 17025 accredited, GMP-compliant facilities in the USA. Every lot of CJC-1295 No DAC undergoes rigorous lot-specific analysis, including full-spectrum RP-HPLC profiling, ESI-MS molecular weight confirmation, and LAL endotoxin testing. Verified Certificate of Analysis (COA) documentation is made accessible for every batch. Laboratories seeking bulk reagent supplies for high-throughput screening can establish dedicated accounts via our wholesale procurement platform.
What is the certified purity standard for CJC-1295 No DAC at PX1 Research?
Every lot of CJC-1295 No DAC supplied by PX1 Research is verified via RP-HPLC to meet or exceed 98% peptide purity.
How is the molecular identity of CJC-1295 No DAC confirmed?
Identity is confirmed using Electrospray Ionization Mass Spectrometry (ESI-MS), validating the theoretical molecular weight of 3367.9 Da.
What analytical documents are provided with each order?
Each lot comes with a lot-specific Certificate of Analysis (COA) displaying raw RP-HPLC chromatograms, mass spectrometry reports, and LAL endotoxin quantification data.
What is the structural difference between CJC-1295 No DAC and CJC-1295 with DAC?
CJC-1295 No DAC lacks the Drug Affinity Complex (maleimido-propionic acid linker), resulting in a shorter half-life that preserves physiological pulsatile GH release, whereas the DAC version covalently binds albumin for extended clearance times.
How should lyophilized CJC-1295 No DAC be stored in the lab?
Lyophilized vials should be stored desiccated at -20°C or -80°C to ensure long-term stability and prevent moisture-induced degradation.
What reconstitution diluents are suitable for in vitro research?
Reconstitution is typically performed using sterile Bacteriostatic Water or Sterile Water for Injection, depending on cell culture sensitivity and downstream assay conditions.
Why is endotoxin testing critical for CJC-1295 No DAC?
Endotoxins cause non-specific inflammatory cytokine release in cell cultures and animal models, confounding biological data. PX1 Research ensures endotoxin levels remain below 0.1 EU/mg.
Can CJC-1295 No DAC be ordered in bulk for institutional research?
Yes, verified academic and commercial research entities can procure bulk lots and request specialized batch testing through our wholesale laboratory program.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.